Biodesix, Inc.
BDSX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $22 | $20 | $18 | $20 |
| % Growth | 8.7% | 11.5% | -12.1% | – |
| Cost of Goods Sold | $4 | $4 | $4 | $4 |
| Gross Profit | $18 | $16 | $14 | $16 |
| % Margin | 81.1% | 79.9% | 79.4% | 78.7% |
| R&D Expenses | $3 | $3 | $3 | $2 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $22 | $22 | $20 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25 | $26 | $23 | $23 |
| Operating Income | -$7 | -$10 | -$9 | -$7 |
| % Margin | -32.4% | -48.6% | -50.9% | -32.5% |
| Other Income/Exp. Net | -$2 | -$2 | -$2 | -$2 |
| Pre-Tax Income | -$9 | -$11 | -$11 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$11 | -$11 | -$8 |
| % Margin | -40% | -57.3% | -61.8% | -40.4% |
| EPS | -1.16 | -1.6 | -1.6 | -1.2 |
| % Growth | 27.5% | 0% | -33.3% | – |
| EPS Diluted | -1.16 | -1.6 | -1.6 | -1.2 |
| Weighted Avg Shares Out | 8 | 7 | 7 | 7 |
| Weighted Avg Shares Out Dil | 8 | 7 | 7 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$5 | -$8 | -$8 | -$5 |
| % Margin | -24% | -40.8% | -44.6% | -25% |